How much is Be Biopharma worth in 2026?

Be Biopharma has a current valuation of N/A based on their Later Stage VC round and secondary market data.

How much funding has Be Biopharma raised?

Be Biopharma has raised $274.0M in total funding across 2 funding rounds.

Be Biopharma

Drug DiscoveryWebsite

Be Biopharma valuation and funding history | Last updated: October 1, 2024 | 2 funding rounds

Current Valuation

N/A

As of October 1, 2024

Total Funding Raised

$274.0M

Across 2 rounds

Last Round

Later Stage VC

$92.0M

Last Funding

Oct 2024

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
October 1, 2024	Later Stage VC (Series C)	$92.0M	N/A	-
April 14, 2022	Early Stage VC (Series B)	$130.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Be Biopharma is currently valued at N/A as of October 1, 2024. The company has raised a total of $274.0M in funding across 2 funding rounds.

Track Be Biopharma Valuation Updates

Get notified when Be Biopharma raises new funding or valuation changes

Explore More Data

Detailed analysis for Be Biopharma

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Be Biopharma's valuation history, funding rounds, and growth metrics.

No credit card required

What is Be Biopharma Worth in 2026?

Be Biopharma is a leading private company in the Drug Discovery sector. Track Be Biopharma's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Be Biopharma Valuation is Determined

Private company valuations like Be Biopharma's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.